TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma

The treatment of renal cell carcinoma (RCC) with chemotherapy remains a challenge; therefore, improving the knowledge of the molecular mechanisms underlying RCC chemoresistance and developing novel therapeutic strategies is important. Dedicator of cytokinesis 1 (DOCK1), the first member of the DOCK...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wei, Zheng, Xiaoxiao, Xie, Shangzhi, Zhang, Shufen, Mao, Jiayan, Cai, Ying, Lu, Xuemei, Chen, Wei, Ni, Haibin, Xie, Liping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339706/
https://www.ncbi.nlm.nih.gov/pubmed/32626999
http://dx.doi.org/10.3892/mmr.2020.11243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339706/
https://www.ncbi.nlm.nih.gov/pubmed/32626999
http://dx.doi.org/10.3892/mmr.2020.11243

Ejemplares similares